18F-FDG PET/CT双时相成像预测乳腺浸润性导管癌的临床分子分型
本研究回顾性分析164例经病理证实的乳腺浸润性导管癌女性的18F-FDG PET/CT双时相成像数据,测量早期和延迟期SUVmax(SUVmax1、SUVmax2)并计算滞留指数(RI)。结果显示,三阴性乳腺癌(TNBC)组SUVmax1和SUVmax2最高,Luminal A组最低(p<0.001);TNBC和HER2过表达组的RI高于Luminal A和B组(p<0.001)。SUVmax2对ER阴性、PR阴性、Ki67高表达状态的诊断AUC分别为0.852、0.858、0.915,SUVmax1对HER2阳性的AUC为0.714。结论认为18F-FDG PET/CT双时相成像有助于预测乳腺浸润性导管癌的分子标志物表达和亚型,从而制定更个体化的治疗方案。
要点
- 双时相PET/CT中,TNBC组SUVmax1、SUVmax2最高,Luminal A组最低。
- TNBC和HER2过表达组的RI高于Luminal A和B组。
- SUVmax2对Ki67高表达的诊断AUC最高(0.915),阈值10.21。
关键影像表现/征象
- TNBC组SUVmax1和SUVmax2最高,Luminal A组最低(p<0.001)。
- TNBC和HER2过表达组的RI高于Luminal A和B组(p<0.001),TNBC与HER2过表达组间、Luminal A与B组间RI无显著差异(p=0.640和0.345)。
- ER阴性组和PR阴性组的SUVmax1、SUVmax2、RI均显著高于PR阳性组(p<0.001)。
- HER2阳性组SUVmax1和SUVmax2高于阴性组(p<0.001),但RI无显著差异(p=0.904)。
- Ki67高表达组SUVmax1和SUVmax2高于低表达组(p<0.001),但RI无显著差异(p=0.216)。
诊断标准与关键数值
- ER阴性vs阳性:SUVmax2的AUC最大为0.852,诊断阈值10.87,敏感度79.6%,特异度74.5%。
- PR阴性vs阳性:SUVmax2的AUC为0.858,诊断阈值10.45,敏感度83.1%,特异度75.3%。
- HER2阴性vs阳性:SUVmax1的AUC为0.714,诊断阈值9.28,敏感度79.6%,特异度60.9%。
- Ki67高表达vs低表达:SUVmax2的AUC最大为0.915,诊断阈值10.21,敏感度83.4%,特异度93.9%。
临床应用与阅片要点
- 双时相PET/CT测量SUVmax1、SUVmax2和RI,可无创提示乳腺浸润性导管癌的分子亚型。
- 高SUVmax2(如>10.21)提示Ki67高表达可能,有助于评估肿瘤增殖活性。
- RI在TNBC和HER2过表达组较高,可辅助区分Luminal型与非Luminal型。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To investigate the diagnostic value of Fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (18F-FDG PET/CT) dual-phase imaging for the different molecular subtypes of invasive ductal carcinoma of the breast.
MATERIALS AND METHODS: Clinical imaging data of 164 women with invasive ductal carcinoma of the breast confirmed by pathology who underwent 18F-FDG PET/CT dual-phase imaging were retrospectively analyzed. The maximum standard uptake values (SUVmax) of the early and delayed phases of the lesion were measured and recorded as SUVmax1 and SUVmax2, respectively, and the retention index (RI) was calculated. We analyzed the change rule of SUVmax1, SUVmax2, and RI for the different molecular subtypes and molecular marker expression groups. The diagnostic threshold of different molecular marker expression status was determined using receiver operating characteristic curve analysis.
RESULTS: SUVmax1 and SUVmax2 were highest in the TNBC group and lowest in the luminal A group (p<0.001). TNBC and HER2 overexpression groups had higher RI than the luminal A and B groups (p<0.001), with no significant difference between the TNBC and HER2 overexpression groups or between the luminal A and B groups (p=0.640 and 0.345, respectively). The ER- and PR-negative groups had significantly higher SUVmax1, SUVmax2, and RI than the PR-positive group (p<0.001). The HER2-positive group had higher SUVmax1 and SUVmax2 than the negative group (p<0.001). The Ki67 overexpression group had higher SUVmax1 and SUVmax2 levels than the low expression group (p<0.001). There was no significant difference in RI between HER2-positive and negative groups or between Ki67 high and low expression groups (p=0.904 and 0.216, respectively). For ER-negative and positive expression status, the maximum area under the curve (AUC) of SUVmax2 was 0.852, diagnostic threshold was 10.87, sensitivity was 79.6%, and specificity was 74.5%. For PR-negative and positive expression status, the AUC of SUVmax2 was 0.858, diagnostic threshold was 10.45, sensitivity was 83.1%, and specificity was 75.3%. For HER2-negative and positive expression status, the AUC of SUVmax1 was 0.714, diagnostic threshold was 9.28, sensitivity was 79.6%, and specificity was 60.9%. For Ki67 high- and low expression status, the AUC of SUVmax2 was 0.915 at maximum, diagnostic threshold was 10.21, sensitivity was 83.4%, and specificity was 93.9%.
CONCLUSION: 18F-FDG PET/CT dual-phase imaging facilitates the prediction of the expression of molecular markers and subtypes of invasive ductal carcinoma of the breast and the development of more tailored treatment plans for patients with this disease.
引用
- Zhang, Liu, Fan, et al. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using 18F-FDG PET/CT Dual-Phase Imaging. Acad Radiol. 2023. PMID: 36624021. doi:10.1016/j.acra.2022.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。